ESMO WCGIC 2021 | Treatment of CRC in adjuvant setting

Deborah Mukherji, MBBS, FRCP, American University of Beirut Medical Center, Beirut, Lebanon discusses the state of the art in treating colorectal cancer (CRC) in the adjuvant setting. Current research is focusing on using circulating biomarkers, DNA and tumor cells (CTCs), alongside clinical and pathological risk factors, to guide adjuvant therapy. Circulating biomarkers may be used to risk-stratify patients to inform the duration and intensity of adjuvant therapy. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.